The Impact of Metformin on the Outcome of Gouty Arthritis in a Cohort of Egyptian Gouty Patients.
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Objective:
To study the impact of metformin on the outcome of gouty arthritis in a cohort of Egyptian
gouty patients, and to evaluate its effect on local joint inflammation, inflammatory
cytokines (IL-1β and IL-6), and life quality.
Methods:
A prospective randomized, single-blinded parallel randomized control study included 250
patients with active inflammatory gouty arthritis were randomized to receive metformin
(1000mg/day) or placebo in addition to the traditional lines of treatment of gout. The
clinical and laboratory data of the patients will be analyze at baseline, then after 6, and
12 months, with the assessment of gout disease activity, in addition, serum IL-1β and IL-6,
the number of attacks per year, treatment satisfaction, quality of life, and disability index
were evaluated at the 12th month from starting metformin and placebo therapy.